UNIGE document Scientific Article
previous document  unige:1037  next document
add to browser collection

At the horizon of innovative therapy in rheumatology: new biologic agents

Published in Current opinion in rheumatology. 2008, vol. 20, no. 3, p. 269-275
Abstract PURPOSE OF REVIEW: To review the rational and the results regarding the use of novel biologic agents in inflammatory rheumatic diseases. RECENT FINDINGS: Recent findings show that excessive IL-1 processing and release contribute to different rheumatic conditions, including periodic fever syndromes, systemic-onset juvenile idiopathic arthritis, adult Still's disease, and crystal-induced arthritis. Preliminary results indicate that administration of IL-1 receptor antagonist and other IL-1 inhibitors improves these conditions. IL-6 also plays a major role in the control of inflammatory responses. Several clinical trials have shown that inhibition of IL-6 by a monoclonal antibody against its receptor is efficacious in rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis patients. Accumulating evidence indicates that other cytokines, including IL-15, IL-18, and IL-21 may also play an important role in rheumatoid arthritis. Several signaling pathways involved in the immune and inflammatory responses may also constitute novel targets. Preliminary data on an agent targeting the Janus kinase/Signal transducer and activators of transcription pathway are encouraging. SUMMARY: Beyond tumor necrosis factor alpha targeting, the use of inhibitors against other cytokines and cytokine-induced intracellular responses is leading to a promising therapy in the future.
Keywords Antibodies, Monoclonal/therapeutic useClinical Trials as TopicHumansImmunologic Factors/immunology/therapeutic useInterleukins/immunologyReceptors, Interleukin/antagonists & inhibitorsRheumatic Diseases/drug therapy/immunologySignal Transduction/drug effects
PMID: 18388517
Full text
Research group Mécanisme de l'inflammation articulaire (44)
(ISO format)
FINCKH, Axel, GABAY, Cem. At the horizon of innovative therapy in rheumatology: new biologic agents. In: Current opinion in rheumatology, 2008, vol. 20, n° 3, p. 269-275. doi: 10.1097/BOR.0b013e3282fa13b4 https://archive-ouverte.unige.ch/unige:1037

476 hits



Deposited on : 2009-02-27

Export document
Format :
Citation style :